**Article title:** The Impact of Drug Trials With Financial Conflict of Interests on the Meta-analyses: A Meta-epidemiological Study

**Journal name:** International Journal of Health Policy and Management (IJHPM)

**Authors’ information:** Na Zhang\(^{1,2,3,4}\)¶, Peijing Yan\(^5\)¶, Haitong Zhao\(^{1,2,3,4}\), Lufang Feng\(^{1,2,3,4}\), Xiajing Chu\(^{1,2,3,4}\), Jingwen Li\(^{1,2,3,4}\), Nan Chen\(^{1,2,3,4}\), Kehu Yang\(^{1,2,3,4}\)*, Xingrong Liu\(^1\)*

1Evidence Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, China.

2Health Technology Assessment Center of Lanzhou University, School of Public Health, Lanzhou University, Lanzhou, China.

3Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.

4Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China.

5Department of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China

¶Both authors contributed equally to this paper.

(*Corresponding author: kehuyangebm2006@126.com & liuxr@lzu.edu.cn)

**Supplementary file 1**
| Study                | Trials included MA | Funding source of MA | Author-industry financial ties of MA | Funding source of included trials (n = 964) | Author-industry financial ties of included trials (n = 964) |
|----------------------|--------------------|----------------------|--------------------------------------|---------------------------------------------|-------------------------------------------------------------|
|                      |                    |                      |                                      | No. pharmaceutical industry & No. non-profit organization & No. NR & No. none known | No. existing author-industry financial ties & No. NR & No. none known |
| Brand, 2010          | 9                  | None known          | None known                          | 1 & 0 & 3 & 2 & 3                          | 1 & 1 & 7                                                      |
| Marshall, 2010       | 38                 | None known          | None known                          | 17 & 4 & 3 & 6 & 8                         | 12 & 9 & 17                                                    |
| Stowe, 2010          | 44                 | None known          | Yes                                  | 17 & 0 & 12 & 0 & 15                       | 15 & 0 & 29                                                    |
| Martin-Hirsch, 2011  | 7                  | Non-profit organization | None known                       | 2 & 0 & 2 & 0 & 3                         | 1 & 0 & 6                                                      |
| Zani, 2011           | 19                 | None known          | None known                          | 6 & 0 & 3 & 0 & 10                        | 7 & 0 & 12                                                    |
| Chauhan, 2012        | 65                 | Non-profit organization | None known                       | 0 & 0 & 13 & 25 & 27                  | 0 & 29 & 36                                                    |
| Sinclair, 2012       | 8                  | Non-profit organization | None known                       | 1 & 0 & 2 & 0 & 5                         | 0 & 0 & 8                                                      |
| Nair, 2012           | 17                 | Non-profit organization | None known                       | 3 & 1 & 3 & 4 & 6                         | 2 & 6 & 9                                                      |
| Lodi, 2012           | 18                 | Non-profit organization | None known                       | 7 & 0 & 1 & 3 & 7                        | 9 & 6 & 3                                                      |
| Rudic, 2012          | 16                 | Non-profit organization | None known                       | 4 & 1 & 3 & 2 & 6                         | 4 & 6 & 6                                                      |
| Anderson-James, 2013 | 2                  | Pharmaceutical industry and non-profit organization | None known                       | 1 & 0 & 1 & 1 & 0                        | 0 & 0 & 2                                                      |
| Brown, 2013          | 10                 | Non-profit organization | Yes                                  | 0 & 0 & 2 & 4 & 4                         | 0 & 3 & 7                                                      |
| Sharma, 2013         | 10                 | Non-profit organization | None known                          | 4 & 0 & 2 & 4 & 0                         | 4 & 0 & 6                                                      |
| Flenady, 2013        | 14                 | Non-profit organization | None known                          | 3 & 1 & 1 & 2 & 7                         | 3 & 2 & 9                                                      |
| Massel, 2013         | 13                 | Non-profit organization | None known                          | 2 & 0 & 2 & 0 & 9                         | 3 & 0 & 10                                                     |
| Sampson, 2013        | 17                 | Non-profit organization | None known                          | 4 & 1 & 6 & 0 & 6                         | 8 & 0 & 9                                                      |
| Prasad, 2014         | 18                 | None known          | None known                          | 1 & 0 & 0 & 0 & 1                         | 0 & 1 & 1                                                      |
| Author, Year | Type | Industry | Company Status | Type |吸引 | 12 | 17 | 34 | 0 | 24 | 39 |
|-------------|------|----------|---------------|------|-----|-----|-----|-----|----|-----|-----|
| Zani, 2014  | 27   | Non-profit organization | None known | 13   | 4   | 6   | 0   | 4   | 8  | 0   | 19 |
| Clarke, 2014 | 6    | Non-profit organization | None known | 2    | 1   | 1   | 1   | 1   | 1  | 2   | 3  |
| Cury Martins, 2015 | 20  | Pharmaceutical industry and non-profit organization | None known | 15   | 0   | 2   | 0   | 3   | 18 | 0   | 2  |
| Dold, 2015  | 63   | Pharmaceutical industry and non-profit organization | Yes | 0    | 0   | 12  | 17  | 34  | 0  | 24  | 39 |
| Sherlock, 2015 | 6  | Non-profit organization | None known | 2    | 3   | 0   | 1   | 3   | 1  | 3   | 2  |
| Tanner, 2015 | 15   | Pharmaceutical industry and non-profit organization | None known | 9    | 1   | 1   | 0   | 4   | 7  | 0   | 8  |
| Chande, 2016 | 13   | Non-profit organization | Yes | 5    | 0   | 3   | 0   | 5   | 4  | 0   | 9  |
| Conway, 2016 | 30   | Non-profit organization | None known | 16   | 2   | 2   | 3   | 7   | 14 | 5   | 11 |
| Nielsen, 2016 | 6   | Non-profit organization | None known | 2    | 0   | 1   | 1   | 2   | 2  | 1   | 3  |
| Rateehalli, 2016 | 15 | Non-profit organization | None known | 3    | 0   | 4   | 0   | 8   | 4  | 0   | 11 |
| Mbuagbaw, 2016 | 12  | Pharmaceutical industry and non-profit organization | None known | 2    | 0   | 3   | 0   | 7   | 2  | 0   | 10 |
| Wang, 2016  | 41   | Non-profit organization | Yes | 0    | 0   | 9   | 14  | 18  | 0  | 21  | 20 |
| Zhu, 2016   | 6    | Pharmaceutical industry and non-profit organization | None known | 0    | 0   | 2   | 2   | 2   | 0  | 2   | 4  |
| Derry, 2017 | 6    | Non-profit organization | Yes | 2    | 1   | 0   | 0   | 3   | 1  | 0   | 5  |
| Knightly, 2017 | 6   | Non-profit organization | None known | 1    | 0   | 0   | 1   | 3   | 0  | 2   | 4  |
| Onland, 2017 | 8    | None known | None known | 1    | 0   | 1   | 0   | 6   | 2  | 0   | 4  |
| Robertson, 2017 | 6   | Non-profit organization | None known | 1    | 0   | 0   | 1   | 4   | 1  | 2   | 3  |
| Shah, 2017  | 2    | None known | None known | 1    | 0   | 1   | 0   | 0   | 0  | 0   | 2  |
| Tickell-Painter, 2017 | 6   | Non-profit organization | None known | 1    | 0   | 1   | 0   | 4   | 1  | 0   | 5  |
| Verbeeck, 2017 | 20  | Non-profit organization | None known | 4    | 2   | 5   | 2   | 7   | 7  | 3   | 10 |
| Zaman, 2017 | 196  | Non-profit organization | None known | 52   | 11  | 29  | 35  | 69  | 74 | 38  | 84 |
Table S2. Impact of excluding the trials with FCOIs on the conclusion of effectiveness.

| Study                | Statistical Method | Effect Estimate | P value | I² |
|----------------------|--------------------|-----------------|---------|----|
|                      |                    | Original        | Recalculated | Original | Recalculated | Original | Recalculated |
| Brand, 2010          | RR (fixed model)   | 0.57 (0.34, 0.94) | 0.45 (0.22, 0.92) | .028 | .030 | 0 | 10 |
| Marshall, 2010       | OR (random model)  | 1.65 (1.11, 2.45) | 0.15 (0.08, 0.22) | .010 | < .001 | 0 | 0 |
| Stowe, 2010          | MD (fixed model)   | -1.54 (-1.83, -1.26) | -1.10 (-1.33, -0.86) | < .001 | < .001 | 36 | 42 |
| Martin-Hirsch, 2011  | RR (random model)  | 0.86 (0.56, 1.32) | 0.64 (0.27, 0.97) | .490 | .300 | 79 | 90 |
| Zani, 2011           | RR (fixed model)   | 0.25 (0.15, 0.42) | 0.22 (0.12, 0.41) | < .001 | < .001 | 0 | 0 |
| Sinclair, 2012       | RR (fixed model)   | 0.71 (0.62, 0.80) | 0.71 (0.11, 0.98) | < .001 | < .001 | 0 | 15 |
| Nair, 2012           | MD (random model)  | -0.36 (-4.09, 3.38) | 0.92 (0.39, 3.32) | .850 | .530 | 31 | 0 |
| Lodi, 2012           | RR (random model)  | 0.29 (0.16, 0.50) | 0.20 (0.09, 0.74) | < .001 | < .001 | 28 | 0 |

FCOIs: financial conflict of interests; MAs: meta-analyses; NR: not reported.
| Authors             | Model Type | OR (95% CI) | RR (95% CI) | p-value 1 | p-value 2 | Studies |
|---------------------|------------|-------------|-------------|-----------|-----------|---------|
| Rudic, 2012         | RR (fixed model) | 0.97 (0.67, 1.42) | 1.14 (0.52, 2.67) | .890      | .810      | 83      |
| Anderson-James, 2013| OR (fixed model) | 0.61 (0.24, 1.55) | 0.84 (0.63, 0.90) | .300      | .810      | 0       |
| Sharma, 2013        | RR (random model) | 1.13 (1.01, 1.28) | 1.13 (0.96, 1.32) | .040      | .150*     | 82 87    |
| Flenady, 2013       | RR (fixed model) | 1.22 (0.88, 1.69) | 2.11 (0.78, 5.73) | .240      | .140      | 0       |
| Massel, 2013        | OR (fixed model) | 0.43 (0.32, 0.59) | 0.45 (0.33, 0.62) | <.001     | <.001     | 0       |
| Sampson, 2013       | RR (fixed model) | 2.46 (1.70, 3.54) | 2.09 (0.44, 3.01) | <.001     | .007      | 49      |
| Prasad, 2014        | RR (fixed model) | 0.43 (0.30, 0.62) | 0.46 (0.29, 0.72) | <.001     | <.001     | 0       |
| Zani, 2014          | RR (fixed model) | 0.41 (0.21, 0.80) | 0.38 (0.19, 0.76) | .010      | .006      | 49 55    |
| Clarke, 2014        | RR (fixed model) | 5.60 (4.02, 7.81) | 5.46 (3.61, 8.24) | <.001     | <.001     | 50 0     |
| Cury Martins, 2015  | RR (fixed model) | 0.82 (0.72, 0.92) | 0.80 (0.66, 0.98) | .001      | .030      | 0       |
| Tanner, 2015        | OR (random model) | 0.40 (0.07, 2.25) | 0.67 (0.26, 3.09) | .300      | .420      | 0       |
| Chande, 2016        | RR (random model) | 1.53 (1.05, 2.22) | 1.75 (0.58, 5.27) | .026      | .320*     | 64 86    |
| Nielsen, 2016       | RR (random model) | 0.69 (0.39, 1.22) | 1.24 (0.83, 1.85) | .200      | .300      | 68 23    |
| Ratelehalli, 2016   | RR (random model) | 0.69 (0.62, 0.78) | 0.65 (0.55, 0.76) | <.001     | <.001     | 25 0     |
| Mbuagbaw, 2016      | RR (random model) | 1.04 (0.99, 1.09) | 1.04 (0.51, 1.74) | .110      | .230      | 0       |
| Derry, 2017         | RD (fixed model) | -0.04 (-0.16, 0.08) | 0.00 (-0.22, 0.22) | .560      | 1.000     | 0       |
| Knightly, 2017      | MD (fixed model) | 3.34 (-1.58, 8.26) | 6.02 (0.48, 0.86) | .180      | .040*     | 43 31    |
| Onland, 2017        | RR (fixed model) | 0.60 (0.49, 0.98) | 0.64 (0.35, 0.94) | <.001     | .003      | 86 0     |
| Robertson, 2017     | Peto OR (fixed model) | 0.69 (0.56, 0.93) | 1.08 (0.07, 1.34) | .041      | .070*     | 0       |
| Shah, 2017          | RR (random model) | 0.83 (0.56, 1.23) | 0.89 (0.32, 1.17) | .360      | .400      | 0       |
| Tickell-Painter, 2017| RR (random model) | 0.09 (0.04, 0.19) | 0.06 (0.07, 0.48) | <.001     | <.001     | 53 0     |
| Zaman, 2017         | RR (fixed model) | 1.13 (0.83, 1.54) | 0.92 (0.04, 1.89) | .450      | .740      | 18 0     |
| Gallos, 2018        | RR (random model) | 1.26 (1.11, 1.43) | 0.94 (0.60, 1.49) | <.001     | .800*     | 0       |
| Romantsik, 2018     | RR (fixed model) | 7.48 (4.91, 11.38) | 7.35 (4.65, 11.64) | <.001     | <.001     | 27 35    |
| Sliwka, 2018        | OR (random model) | 6.12 (0.73, 51.24) | 5.20 (0.25, 109.37) | .090      | .290      | 0       |
| Tenforde, 2018      | RR (random model) | 0.90 (0.45, 1.77) | 1.13 (0.34, 0.94) | .750      | .810      | 24 51    |
Table S3. Impact of excluding the trials with FCOIs on the conclusion of major adverse events.

| Study             | Statistical Method | Effect Estimate | P value   | I² | Study             | Statistical Method | Effect Estimate | P value   | I² |
|-------------------|--------------------|-----------------|-----------|----|-------------------|--------------------|-----------------|-----------|----|
|                   |                    | Original        | Recalculated |     |                   |                    | Original        | Recalculated |     |                   |                    | Original        | Recalculated |     |
| Stowe, 2010       | Peto OR (fixed model) | 1.20 (1.00, 1.43) | 1.13 (0.89, 1.43) | .046 | Lodi, 2012        | RR (random model)  | 1.98 (1.10, 3.59) | 1.49 (1.16, 8.64) | .023 | Prasad, 2014      | RR (fixed model)  | 0.43 (0.30, 0.62) | .043 | .001 | 48 |
|                   |                    |                 |            | .330* | Sherlock, 2015    | RR (fixed model)   | 1.09 (0.95, 1.26) | 1.03 (0.86, 1.22) | .220 | Nielsen, 2016     | RR (random model)  | 1.10 (0.64, 1.91) | 1.13 (0.64, 1.97) | .720 | 54 |
|                   |                    |                 |            |       |                  |                    |                 |           |     | Rattehalli, 2016 | RR (random model)  | 1.56 (1.13, 2.15) | 1.44 (0.97, 2.94) | .007 | 7 |
|                   |                    |                 |            |       |                  |                    |                 |           |     | Mbuagbaw, 2016    | RR (random model)  | 0.91 (0.71, 1.18) | 0.89 (0.62, 1.27) | .500 | 43 |
|                   |                    |                 |            |       |                  |                    |                 |           |     | Wang, 2016        | RR (fixed model)   | 1.07 (0.82, 1.40) | 1.03 (0.76, 1.42) | .610 | 41 |
|                   |                    |                 |            |       |                  |                    |                 |           |     | Derry, 2017       | RD (fixed model)   | 0.04 (-0.02, 0.09) | 0.02 (-0.06, 0.10) | .210 | 45 |
|                   |                    |                 |            |       |                  |                    |                 |           |     | Knightly, 2017    | RD (fixed model)   | -0.01 (-0.05, 0.03) | 0.02 (-0.06, 0.09) | .540 | 0 |

FCOIs: financial conflict of interests; RR: risk ratio; OR: odds ratio; MD: mean difference; Peto OR: Peto odds ratio; SMD: standardized mean difference.

*: The conclusion changed from statistical significance to no statistical significance.

#: The conclusion changed from no statistical significance to statistical significance.
| Study                  | Statistical Method | Effect Estimate |       |       |       |       | I²     |       |       |       |       |       |       |       |       |
|-----------------------|--------------------|-----------------|-------|-------|-------|-------|--------|-------|-------|-------|-------|-------|-------|-------|-------|
|                       | RR (fixed model)   |                 |       |       |       |       |        |       |       |       |       |       |       |       |       |
| Shen, 2017            |                    | 0.94 (0.68, 1.19) | 0.76 (0.37, 1.57) | .690 | .460 | 2 | 35 |
| Tickell-Painter, 2017 | RR (fixed model)   | 0.70 (0.14, 3.53) | 0.94 (0.13, 6.62) | .660 | .950 | 0 | 0 |
| Verbeeck, 2017        | RR (fixed model)   | 1.20 (0.35, 4.10) | 0.20 (0.01, 4.01) | .770 | .290 | 49 | 69 |
| Zaman, 2017           | RR (fixed model)   | 0.15 (0.06, 0.39) | 0.12 (0.02, 0.92) | <.001 | .040 | 0 | 0 |
| Gallos, 2018          | RR (random model)  | 0.62 (0.14, 2.74) | 0.62 (0.14, 2.74) | .530 | .530 | 0 | 0 |
| Mehta, 2018           | Peto OR (fixed model) | 5.66 (3.62, 8.84) | 4.85 (3.01, 7.81) | <.001 | <.001 | 0 | 0 |
| Panebianco, 2018      | RR (fixed model)   | 0.19 (0.46,0.93) | 0.81 (0.53, 1.23) | .041 | .330* | 23 | 32 |
| Romantsik, 2018       | RR (fixed model)   | 8.35 (5.31, 13.12) | 7.05 (4.43, 11.21) | <.001 | <.001 | 29 | 18 |
| Sliwka, 2018          | RR (random model)  | 0.96 (0.50, 1.83) | 0.90 (0.33, 2.40) | .900 | .830 | 0 | - |
| Gagyor, 2019          | RR (fixed model)   | 1.16 (0.83, 1.63) | 1.08 (0.69, 1.67) | .390 | .740 | 0 | 0 |
| Solomon, 2019         | RR (fixed model)   | 0.40 (0.36, 0.441) | 0.42 (0.38, 0.46) | <.001 | <.001 | 82 | 4 |
| Toupin April, 2019    | RR (fixed model)   | 0.65 (2.20, 3.19) | 3.25 (2.27, 4.64) | <.001 | <.001 | 45 | 17 |

Peto OR: Peto odds ratio; RR: risk ratio; RD: risk difference.
*: The conclusion changed from statistical significance to no statistical significance.

Table S4. Impact of excluding the trials with FCOI on the conclusion of serious adverse events.

FCOIs: financial conflict of interests; RR: risk ratio.
Table S5. Impact of trials without reported FCOIs on the conclusion of effectiveness.

| Study            | Statistical Method | Effect Estimate | P value | F²   |
|------------------|--------------------|----------------|---------|------|
|                  |                    | Original       | Recalculated | Original | Recalculated | Original | Recalculated |
| Brand, 2010      | RR (fixed model)   | 0.57 (0.34, 0.94) | 0.58 (0.25, 1.35) | .028 | .210 | 0 | 33 |
| Marshall, 2010   | OR (random model)  | 1.65 (1.11, 2.45) | 0.13 (0.02, 0.24) | .010 | .020 | 0 | 0 |
| Chauhan, 2012    | RR (random model)  | 1.51 (1.17, 1.96) | 1.89 (1.59, 2.34) | .002 | .009 | 42 | 28 |
| Nair, 2012       | MD (random model)  | -0.36 (-4.09, 3.38) | -6.96 (-18.78, 4.87) | .850 | .250 | 31 | 71 |
| Brown, 2013      | MD (random model)  | -3.66 (-5.28, -2.05) | -2.66 (-7.99, -2.67) | <.001 | <.001 | 60 | 83 |
| Dold, 2015       | RR (random model)  | 0.93 (0.87, 1.00) | 0.99 (0.58, 1.69) | .046 | .097* | 0 | 66 |
| Sherlock, 2015   | RR (fixed model)   | 2.25 (1.50, 3.39) | 1.98 (1.26, 3.09) | <.001 | .003 | 79 | 0 |
| Conway, 2016     | RR (random model)  | 0.94 (0.48, 1.84) | 1.03 (0.38, 2.82) | .850 | .950 | 71 | 81 |
| Wang, 2016       | RR (fixed model)   | 0.69 (0.62, 0.77) | 0.61 (0.51, 0.74) | <.001 | <.001 | 15 | 0 |
| Zhu, 2016        | MD (fixed model)   | -0.14 (-0.20, -0.08) | -0.28 (-0.41, -0.15) | <.001 | <.001 | 68 | 0 |
| Robertson, 2017  | Peto OR (fixed model) | 0.69 (0.56, 0.93) | 0.56 (0.25, 0.97) | .041 | .038 | 0 | 0 |
| Tickell-Painter, 2017 | RR (random model) | 0.09 (0.04, 0.19) | 0.02 (0.01, 0.07) | <.001 | <.001 | 53 | 67 |
| Zaman, 2017      | RR (fixed model)   | 1.13 (0.83, 1.54) | 1.07 (0.56, 2.03) | .450 | .850 | 18 | 0 |
| Gallos, 2018     | RR (random model)  | 1.26 (1.11, 1.43) | 1.29 (1.13, 1.47) | <.001 | .001 | 0 | 0 |
| Mehta, 2018      | MD (fixed model)   | -2.29 (-6.03, 1.45) | -3.11 (-7.36, 1.15) | .230 | .150 | 0 | 71 |
| Panbianco, 2018  | RR (fixed model)   | 1.89 (1.40, 2.55) | 1.94 (1.42, 2.64) | <.001 | <.001 | 0 | 0 |
| Gagyor, 2019     | RR (random model)  | 0.54 (0.38, 0.77) | 0.50 (0.25, 0.97) | <.001 | .040 | 40 | 68 |
| Solomon, 2019    | RR (fixed model)   | 0.57 (0.39, 0.84) | 0.59 (0.38, 0.91) | .005 | .008 | 23 | 0 |
| Toupin April, 2019 | SMD (fixed model)  | -0.25 (-0.23, -0.19) | -0.45 (-0.67, -0.02) | <.001 | <.001 | 0 | 0 |

FCOIs: financial conflict of interests; RR: risk ratio; OR: odds ratio; MD: mean difference; SMD: standardized mean difference.

*: The conclusion changed from statistical significance to no statistical significance.
Table S6. Impact of trials without reported FCOIs on the conclusion of major adverse events.

| Study            | Statistical Method | Effect Estimate | P value | P²       |
|------------------|--------------------|-----------------|---------|----------|
|                  |                    | Original        | Recalculated | Original | Recalculated |
|                  | RR (random model)  | 1.98 (1.10, 3.59) | 3.38 (0.19, 61.03) | .023      | .410*         | 11     | -       |
| Flenady, 2013    | RR (fixed model)   | 1.32 (0.92, 1.89) | 1.53 (0.91, 2.57)  | .130      | .110          | 0      | 38      |
| Prasad, 2014     | RR (fixed model)   | 0.43 (0.30, 0.62) | 0.43 (0.30, 0.62)  | <.001     | <.001         | 48     | -       |
| Clarke, 2014     | RR (fixed model)   | 0.91 (0.74, 1.12) | 0.81 (0.63, 1.05)  | .370      | .110          | 0      | 0       |
| Sherlock, 2015   | RR (fixed model)   | 1.09 (0.95, 1.26) | 1.03 (0.86, 1.23)  | .220      | .770          | 54     | 51      |
| Nielsen, 2016    | RR (random model)  | 1.10 (0.64, 1.91) | 1.13 (0.64, 1.97)  | .720      | .680          | 52     | 55      |
| Wang, 2016       | RR (fixed model)   | 1.07 (0.82, 1.40) | 1.03 (0.76, 1.42)  | .610      | .830          | 41     | 60      |
| Knightly, 2017   | RD (fixed model)   | -0.01 (-0.05, 0.03) | 0.02 (-0.06, 0.09) | .540      | .690          | 0      | 21      |
| Shen, 2017       | RR (fixed model)   | 0.94 (0.68, 1.19) | 0.76 (0.37, 1.57)  | .690      | .460          | 2      | 35      |
| Tickell-Painter, 2017 | RR (fixed model) | 0.70 (0.14, 3.53) | 0.31 (0.01, 7.54)  | .660      | .470          | 0      | -       |
| Zaman, 2017      | RR (fixed model)   | 0.15 (0.06, 0.39) | 0.12 (0.02, 0.92)  | <.001     | .040          | 0      | 0       |
| Mehta, 2018      | Peto OR (fixed model) | 5.66 (3.62, 8.84) | 4.39 (1.45, 13.23) | <.001     | .009          | 0      | 0       |
| Panebianco, 2018 | RR (fixed model)   | 0.79 (0.46, 1.35) | 0.81 (0.53, 1.23)  | .250      | .330          | 23     | 32      |
| Gagyor, 2019     | RR (fixed model)   | 1.16 (0.83, 1.63) | 1.00 (0.36, 2.79)  | .390      | 1.000         | 0      | -       |
| Solomon, 2019    | RR (fixed model)   | 0.40 (0.36, 0.441)| 0.44 (0.36, 0.53)  | <.001     | <.001         | 82     | 0       |
| Toupin April, 2019 | RR (fixed model) | 0.65 (2.20, 3.19) | 3.25 (2.27, 4.64)  | <.001     | <.001         | 45     | 44      |

FCOIs: financial conflict of interests; RR: risk ratio; RD: risk difference; Peto odds ratio;

*: The conclusion changed from statistical significance to no statistical significance.
Table S7. Impact of trials without reported FCOIs on the conclusion of major adverse events.

| Study           | Statistical Method      | Effect Estimate          | P value | P²       |
|-----------------|-------------------------|--------------------------|---------|----------|
|                 |                         | Original                 | Recalculated | Original | Recalculated | Original | Recalculated |
| Rudic, 2012     | Rudic, 2012             | RR (fixed model)         | 0.87 (0.68, 1.12) | .280     | .120     | 23        | 0          |
| Sherlock, 2015  | Sherlock, 2015          | RR (fixed model)         | 3.04 (0.32, 28.99) | .330     | .560     | 0         | 5          |
| Tickell-Painter, 2017 | Tickell-Painter, 2017 | RR (fixed model)         | 0.70 (0.14, 3.53) | .660     | .810     | 0         | 17         |

FCOIs: financial conflict of interests; RR: risk ratio.
Figure S1. Study flow diagram.